Interv Akut Kardiol. 2008;7(6):220-224

Difficulty of anticoagulant therapy in atrial fibrillation - interactions of warfarin with drugs and food

Kateřina Lefflerová
Klinika kardiologie, Institut klinické a experimentální medicíny, Praha

Atrial fibrillation is the most common cardiac arrhythmia, which promotes trombus formation particularly in the left atrium and increases the overall risk of stroke five-fold. One of the main objectives of treating patients with atrial fibrillation is to prevent thrombo-embolism and reduce risk of stroke. Meta-analysis of large randomized trials showed risk reduction of 68 %, adjusted-dose oral anticoagulation is more effective than aspirin against stroke. The optimal intensity of oral anticoagulation in atrial fibrillation is the value of INR 2.0–2.5. Although effective, vitamin K antagonists have narrow therapeutic window, over-anticoagulation increases risk of bleeding, anticoagulant effect is affected by drugs and food containing vitamin K. There is no special „warfarin“ diet, we must recommend diet with constant vitamin K1 content, edify about possible interactions and necessity of more frequent control of INR.

In spite of difficulty, vitamin K antagonists, such as warfarin still remain the only oral anticoagulants currently recommended for the prevention of stroke in patients with a moderate to high risk of stroke.

Keywords: atrial fibrillation, thromboembolic complications, warfarin, drug and food interactions

Published: December 20, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lefflerová K. Difficulty of anticoagulant therapy in atrial fibrillation - interactions of warfarin with drugs and food. Interv Akut Kardiol. 2008;7(6):220-224.
Download citation

References

  1. Cabin HS, Clubb KS, Hall C, et al. Risk for systemic embolization of atrial fibrillation without mitral stenosis. AmJ Cardiol 1990; 65: 1112-1116. Go to original source... Go to PubMed...
  2. Čihák R, Heinc P. Doporučení pro léčbu pacientů s fibrilací síní. CorVasa 2004; 46(5) K 67-77.
  3. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457. Go to original source...
  4. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Europace 2006; 8: 651-745. Go to original source... Go to PubMed...
  5. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870. Go to original source... Go to PubMed...
  6. Rockson SG, Albers GW. Comparing the Guidelines: Anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation. J Am Coll Cardiol 2004; 43: 929-935. Go to original source... Go to PubMed...
  7. Hirsh J, Futer V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy. J Am Coll Cardiol 2003; 41: 1633-1652. Go to original source... Go to PubMed...
  8. Link KP. The discovery of dicumarol and its sequels. Circulation 1959; 19: 97-107. Go to original source... Go to PubMed...
  9. Chlumský J a kolektiv. Antikoagulační léčba. Praha: Grada Publishing a.s., 2005: 220 s.
  10. Malý J, Matýšková M, Penka M. Antikoagulační léčba. Doporučený diagnostický a léčebný postup pro všeobecné praktické lékaře. 1. vyd. Praha: Společnost všeobecného lékařství ČLS JEP, 2005: 8 s.
  11. Lefflerová K. Současná strategie antikoagulační léčby. Postgraduální medicína 2007; 9: 986-992.
  12. Schwarz UI, et al. Genetic determinants of response to warfarin therapy during initial anticoagulation. N Engl J Med 2008; 358(10): 999-1008. Go to original source... Go to PubMed...
  13. Nieuwlaat R, Capucci A, Lip GIH, et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2006; 27: 3018-3026. Go to original source... Go to PubMed...
  14. Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC Members Countries. The Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26: 2422-2434. Go to original source... Go to PubMed...
  15. Hart RG, Benavente O, Mc Bride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492-501. Go to original source... Go to PubMed...
  16. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348(9025): 423-428. Go to original source... Go to PubMed...
  17. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med 1994; 121: 676-683. Go to original source... Go to PubMed...
  18. Booth SL, Charnley JM, Sadowski JA, et al. Dietary vitamin K1 and stability of oral anticoagulation: Proposal of a diet with constant vitamin K1 content. Thromb Haemost 1997; 77(3): 504-509. Go to original source... Go to PubMed...
  19. Booth SL, Centurelli MA. Vitamin K: a practical guide to the dietary management of patients on warfarin. Nutrition Reviews 1999; 57: 288-296. Go to original source... Go to PubMed...
  20. Schulman S. Care of patients receiving long-term anticoagulant therapy. N Engl J Med 2003; 349: 675-683. Go to original source... Go to PubMed...
  21. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-1029. Go to original source... Go to PubMed...
  22. Kortke H, Korfer R. International normalized ratio self-management after mechanical heart valve replacement: is an early start advantegeous? Ann Thorac Surg 2001; 72: 44-48. Go to original source... Go to PubMed...
  23. Kessler P. Antikoagulační léčba warfarinem v roce 2006. Kardioforum 2006; 4(1): 43-51.
  24. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867. Go to original source... Go to PubMed...
  25. The ACTIVE Writing Group on behalf of the ACTIVE investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet 2006; 367: 1903-1912. Go to original source... Go to PubMed...
  26. Turpie AG. New oral anticoagulation in atrial fibrillation. Eur Heart J 2008; 29: 155-165. Go to original source... Go to PubMed...
  27. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct trhrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet 2003; 362: 1691-1698. Go to original source... Go to PubMed...
  28. Halperin JL. Ximelagatran: Oral Direct Thrombin Inhibition as Anticoaulant Therapy in Atrial Fibrillation. J Am Coll Cardiol 2005; 45: 1-9. Go to original source... Go to PubMed...
  29. Weitz JI. New Anticoagulants for Treatment of Venous Thromboembolism. Circulation 2004; 110(9): 19-26. Go to original source... Go to PubMed...
  30. The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: A randomized, open-label, non-inferiority trial. Lancet 2008; 371: 315-321. Go to original source... Go to PubMed...
  31. Karjalainen PP, Porela P, Ylitalo A, et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J 2007; 28(6): 726-732. Go to original source... Go to PubMed...
  32. Sinnaeve PR. The good, the bad, and the ugly: triple therapy after PCI in patients requiring chronic anticoagulation. Eur Heart J 2007; 28(6): 657-658. Go to original source... Go to PubMed...




Interventional Cardiology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.